A leading RNAi therapeutics company.
Alnylam to provide data on RNAi therapeutics for fibrotic diseases at The Liver Meeting Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today it’ll present several poster presentations at the 61st Annual Achieving of the American Association for the Study of Liver Illnesses becoming held in Boston, Mass from October 29 – November 2, 2010 http://finasteride1canada.com/hair-loss-causes-and-treatment.html . At the meeting, new research related to the business’s pre-clinical and scientific pipeline efforts will be offered, including new data showing effective delivery of RNAi therapeutics to hepatic stellate cells.
Alnylam publishes research results of Sort1 gene function in coronary disease development Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics business, announced today the publication of new research findings in the journal Character describing the discovery and validation of the function of the gene Kind1 in the advancement of coronary disease, including myocardial infarction . This work was done with collaborators at University of Pennsylvania School of Medication, Massachusetts General Hospital , and the Broad Institute. The collaborative work combined genome-wide association studies and RNAi technology to recognize and validate novel genes as targets for fresh therapies for cardiovascular disease.D., Senior Director, Analysis at Alnylam.